Historically, alkylator-based therapy has been used to treat patients with chronic lymphocytic leukemia (CLL). More effective therapies, such as the use of monoclonal antibodies in combination with chemotherapy, have been shown to prolong both progression-free survival and overall survival. Improvements in the identification of prognostic markers for CLL, as well as novel combinations for chemoimmunotherapy regimens, have improved the outcome for patients with CLL.
Methods
We examine the diagnosis of CLL, the role of prognostic factors in determining treatment goals, and current data on frontline management of CLL.
Results
The benefits of single-agent and combination therapies are associated with prolonged progression-free and overall survival. While more aggressive management may therefore be warranted, each patient's comorbidities and performance status must be weighed against the benefits, availability, cost, treatment goals, and incidence of adverse effects associated with each therapy.
Conclusions
New single agents and novel treatment combinations have shown promising results in phase I/II studies. The ultimate therapeutic goals of prolonged survival and improved quality of life will be validated only by ongoing clinical and laboratory research and by continuous enrollment of patients in clinical trials.
References
1.
National Cancer Institute.Surveillance Epidemiology and End Results Stat Fact Sheets: Chronic Lymphocytic Leukemia.http://seer.cancer.gov/statfacts/html/cll.html. Accessed May 8, 2011.
2.
WierdaW.G., KeatingM.J., O'BrienS.. Chronic lymphoid leukemias. In: DeVitaVTJr, LawrenceT.S., RosenbergS.A., eds. Cancer: Principles and Practice of Oncology.8th ed.Philadelphia PA: Lippincott Williams & Wilkins; 2008: 2279–2293.
3.
MaloneK.E., KoepsellT.D., DalingJ.R.. Chronic lymphocytic leukemia in relation to chemical exposures.Am J Epidemiol.1989; 130(6): 1152–1158.
4.
BizzozeroOJJr, JohnsonK.G., CioccoA.. Radiation-related leukemia in Hiroshima and Nagasaki 1946-1964. II.Ann Intern Med.1967; 66(3): 522–530.
5.
YuilleM.R., MatutesE., MarossyA.. Familial chronic lymphocytic leukemia: a survey and review of published studies.Br J Haematol.2000; 109(4): 794–799.
6.
HallekM.. State-of-the-art treatment of chronic lymphocytic leukemia.Hematology Am Soc Hematol Educ Program.2009; 440–449.
7.
HallekM., ChesonB.D., CatovskyD.. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute — Working Group 1996 guidelines.Blood.2008; 111(12): 5446–5456.
BinetJ.L., AuquierA., DighieroG.. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.Cancer.1981; 48(1): 198–206.
10.
DöhnerH., StilgenbauerS., BennerA.. Genomic aberrations and survival in chronic lymphocytic leukemia.N Engl J Med.2000; 343(26): 1910–1916.
11.
RassentiL.Z., JainS., KeatingM.J.. Relative value of ZAP-70, CD38 and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.Blood.2008; 112(5): 1923–1930.
12.
CLL Trialists’ Collaborative Group.Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials.J Natl Cancer Inst.1999; 91(10): 861–868.
13.
EichhorstB.F., BuschR., StilgenbauerS.. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.Blood.2009; 114(16): 3382–3391.
14.
RaiK.R., PetersonB.L., AppelbaumF.R.. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.N Engl J Med.2000; 343(24): 1750–1757.
15.
LeporrierM., ChevretS., CazinB.. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.Blood.2001; 98(8): 2319–2325.
16.
ChesonB.D., RummellM.J.. Bendamustine: rebirth of an old drug.J Clin Oncol.2009; 27(9): 1492–1501.
17.
KnaufW.U., LissichkovT., AldaoudA.. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.J Clin Oncol.2009; 27(26): 4378–4384.
18.
EichhorstB.F., BuschR., HopfingerG.. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.Blood.2006; 107(3): 885–891.
19.
FlinnI.W., NeubergD.S., GreverM.R.. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chrnic lymphocytic leukemia: US Intergroup Trial E2997.J Clin Oncol.2007; 25(7): 793–798.
20.
CatovskyD., RichardsS., MatutesE.. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial.Lancet.2007; 370(9583): 230–239.
21.
RobakT., BlonskiJ.Z., KasznickiM.. Cladribine with prednisione versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: reportof a prospective, randomized, multicenter trial.Blood.2000; 96(8): 2723–2729.
22.
RobakT., BlonskiJ.Z., Gora-TyborJ.. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2).Blood.2006; 108(2): 473–479.
23.
HuhnD., von SchillingC., WilhelmM.. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.Blood.200198(5): 1326–1331.
24.
ByrdJ.C., MurphyT., HowardR.S.. Rituximab using thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.J Clin Oncol.2001; 19(8): 2153–2164.
HainsworthJ.D., LitchyS., BartonJ.H.. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.J Clin Oncol.2003; 21(9): 1746–1751.
27.
MoneA.P., CheneyC., BanksA.L.. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism.Leukemia.2006; 20(2): 272–279.
28.
JaglowskiS.M., AlinariL., LapalombellaR.. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.Blood.2010; 116(19): 3705–3714.
29.
HillmenP., SkotnickiA.B., RobakT.. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.J Clin Oncol.2007; 25(35): 5616–5623.
30.
StilgenbauerS., DöhnerH.. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy [letter].N Engl J Med.2002; 347(6): 452–453.
31.
LozanskiG., HeeremaN.A., FlinnI.W.. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.Blood.2004; 103(9): 3278–3281.
32.
LundinJ., KimbyE., BjörkholmM.. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as firstline treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).Blood.2002; 100(3): 768–773.
33.
SchulzH., KleinS.K., RehwaldU.. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.Blood.2002; 100(9): 3115–3120.
34.
WoyachJ.A., RuppertA.S., HeeremaN.A.. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.J Clin Oncol.2011; 29(10): 1349–1355.
35.
ByrdJ.C., RaiK., PetersonB.L.. Addition of rituximab to fludara-bine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.Blood.2005; 105(1): 49–53.
36.
KeatingM.J., O'BrienS., AlbitarM.. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophophamide and rituximab as initial therapy for chronic lymphocytic leukemia.J Clin Oncol.2005; 23(18): 4079–4088.
37.
HallekM., FischerK., Fingerle-RowsonG.. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.Lancet.2010; 376(9747): 1164–1174.
38.
BoettcherS., FischerK., StilgenbauerS.. Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab — a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial.Blood.2008; 112: 125–126.
FoonK.A., BoyiadzisM., LandS.R.. Chemoimmunotherapy with low dose fludarabine and cyclophosphamide with high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.J Clin Oncol.2009; 27(4): 498–503.
41.
LamannaN., KalaycioM., MaslakP.. Pentostatin, cyclophosphamide and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.J Clin Oncol.2006; 24(10): 1575–1581.
42.
KayN.E., GeyerS.M., CallT.G.. Combination chemoimmunith-eraoy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.Blood.2007; 109(2): 405–411.
43.
ReynoldsC., Di BellaN., LyonsR.M.. Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophopshamide, and rituximab in B-cell chronic lymphocytic leukemia.Blood (ASH Anuual Meeting Abstracts).2008; 112(11): 327.
44.
WierdaW.G., O'BrienS.M., FaderlS.H.. CFAR, an active frontline regimen for high risk patients with CLL, including those with del 17p.Blood (ASH Annual Meeting Abstracts).2008; 112: 2095.
45.
ParikhS.A., KeatingM., O'BrienS.. Frontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab (CFAR) in high-risk chronic lymphocytic leukemia.Blood (ASH Annual Meeting Abstracts).2009; 114(22): 208. Abstract.
46.
FischerK., CramerP., StilgenbauerS.. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG).Blood (ASH Annual Meeting Abstracts).2009; 114(22): 205.
47.
CastroJ.E., JamesD.F., Sandoval-SusJ.D.. Rituximab in combination with high-dose methylprednisoline for the treatment of chronic lymphocytic leukemia.Leukemia.2009; 23(10): 1779–1789.
48.
BertazzoniP., RabascioC., GigliF.. Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients.Leuk Lymphoma.2010; 51(8): 1485–1493.
49.
WierdaW.G., KippsT.J., DürigJ.. Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial.Blood (ASH Annual Meeting Abstracts).2009; 114(22): 207.
ChenC.I., BergsagelP.L., PaulH.. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.J Clin Oncol.2011; 29(9): 1175–1181.
52.
FerrajoliA., O'BrienS., WierdaW.. Lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia (CLL).Blood (ASH Annual Meeting Abstracts).2008; 112(11): 45.
53.
MoretonP., KennedyB., LucasG.. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.J Clin Oncol.2005; 23(13): 2971–2979.
54.
O'BrienS.M., KantarjianH.M., ThomasD.A.. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.Cancer.2003; 98(12): 2657–2663.
55.
SchweighoferC.D., RitgenM., EichhorstB.F.. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukemia (CLl) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).Br J Haematol.2009; 144(1): 95–98
56.
ByrdJ.C., GribbenJ.G., PetersonB.L.. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.J Clin Oncol.2006; 24(3): 437–443.
57.
GreverM.R., LucasD.M., DewaldG.W.. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III trial E2997.J Clin Oncol.2007; 25(7): 799–804.
58.
GribbenJ.G.. How I treat CLL up front.Blood.2010; 115(2): 187–197.
MorrisonV.A.. Update on prophylaxis and therapy of infection in patients with chronic lymphocytic leukemia.Expert Rev Anticancer Ther.2001; 1(1): 84–90.
61.
OsterbogA., FoàR., BezaresR.F.. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.Leukemia.2009; 23(11): 1980–1988.
